- Drugs
- Wednesday, 27 May 2020
Drugmaker Sanofi to raise over $11 billion by selling its U.S. partner Regeneron shares
Earlier this week, Regeneron had said it would repurchase about $5 billion of its shares directly from Sanofi, without altering their over-a-decade-long partnership.
Sanofi is selling the Regeneron shares at $515.00 per share - a discount of around 5.5% to Regeneron’s closing price of $545.21 on May 26, and raising gross proceeds of $11.1 billion.
Sanofi will continue to own approximately 400,000 shares of Regeneron’s common stock.
Sanofi could end up raising $11.7 billion, if the underwriters on the deal exercise their option to buy up a further 1.2 million Regeneron shares.
The collaboration between Sanofi and Regeneron dates back to 2003 and has resulted in five approved treatments to date - including eczema drug Dupixent - with additional candidates in clinical development.
Investment banks Bank of America Securities, Goldman Sachs, Barclays, BNP Paribas, Citigroup, JP Morgan and Morgan Stanley worked on Sanofi’s Regeneron stake sale.
Related Industry Updates
See how South Africa Anti-Infective Market is Changes during 2019-2027 with an increase in Revenue of $2572.5Mn| Sanofi, Abbott, Pfizer
Oct 27, 2020
Biotin Supplements Market Pegged for Robust Expansion by 2027
Dec 12, 2020
Epilepsy Market is expected to reach US$ 10.7 billion by 2030
Feb 14, 2024
Sialorrhea Treatment Market is expected to reach US$ 1,042.37 million by 2030
Dec 12, 2023
How Coronavirus Pandemic Will Impact Asia Pacific Antibiotics Market? Industry Trends and Developments 2020-2027
Aug 29, 2020
COVID-19 Fallout Drives Major Increases for Driven's Online Cannabis Sales
Mar 17, 2020
Drug Delivery Market is expected to reach US$ 32,54,594.2 million by 2028
May 23, 2023
Follow us on
